Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Not Confirmed
Not Confirmed
12-14 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
TIDES Europe 2024TIDES Europe 2024
Industry Trade Show
Not Confirmed
12-14 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
04 Oct 2022
// BUSINESSWIRE
29 Sep 2022
// PROACTIVEINVESTOR
https://www.proactiveinvestors.co.uk/companies/news/993982/synairgen-assessing-three-clinical-options-for-antiviral-drug-993982.html
20 Sep 2022
// BUSINESSWIRE
07 Sep 2022
// BUSINESSWIRE
05 Sep 2022
// SYNAIRGEN
https://www.synairgen.com/media/company-announce-collaboration-on-universal-trial
16 May 2022
// Chris Yandall DAILY ECHO
https://www.dailyecho.co.uk/news/20143042.synairgen-tests-new-anti-covid-drug/
Details:
There were no significant differences between SNG001, a pH-neutral formulation of interferon-beta for inhalation that is delivered directly into the lungs using a mesh nebuliser. and placebo with respect to primary outcomes of safety, symptom resolution, or virology.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : There were no significant differences between SNG001, a pH-neutral formulation of interferon-beta for inhalation that is delivered directly into the lungs using a mesh nebuliser. and placebo with respect to primary outcomes of safety, symptom resolution,...
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 04, 2022
Details:
SNG001 is a pH-neutral formulation of IFN-beta for inhalation that is delivered directly into the lungs using a mesh nebuliser, which the Company is developing as a potential host-directed antiviral treatment for patients hospitalised with severe viral lung infections.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SNG001 is a pH-neutral formulation of IFN-beta for inhalation that is delivered directly into the lungs using a mesh nebuliser, which the Company is developing as a potential host-directed antiviral treatment for patients hospitalised with severe viral l...
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 20, 2022
Details:
The results suggest that HRV was cleared more rapidly in patients treated with SNG001 (Interferon Beta-1a) than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 (post hoc analysis).
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: SNG001
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results suggest that HRV was cleared more rapidly in patients treated with SNG001 (Interferon Beta-1a) than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 (post hoc analysis).
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 07, 2022
Details:
The collaboration on the UNIVERSAL trial will help provide a better understanding of SNG001 (interferon beta-1) to predict clinical outcomes in patients hospitalised with respiratory symptoms due to infection with a range of respiratory viruses.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: University of Southampton
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 05, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : University of Southampton
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration on the UNIVERSAL trial will help provide a better understanding of SNG001 (interferon beta-1) to predict clinical outcomes in patients hospitalised with respiratory symptoms due to infection with a range of respiratory viruses.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 05, 2022
Details:
SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of patients hospitalized Due to COVID-19.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Synairgen To Present At ATS 2022
Details : SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of patients hospitalized Due to COVID-19.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 05, 2022
Details:
In vitro studies conducted at Viroclinics-DDL in the Netherlands have shown that SNG001 has potent antiviral activity against SARS-CoV-2 Delta and Omicron variants at concentrations that are readily achievable following inhaled delivery of interferon beta.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In vitro studies conducted at Viroclinics-DDL in the Netherlands have shown that SNG001 has potent antiviral activity against SARS-CoV-2 Delta and Omicron variants at concentrations that are readily achievable following inhaled delivery of interferon bet...
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 03, 2022
Details:
SNG001 is being investigated for possible use in COVID-19 patients. SNG001 has been administered to hospitalised patients on top of standard of care which changed substantially between the Phase 2 and Phase 3 trials.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2022
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Topline Results From Phase 3 SPRINTER trial
Details : SNG001 is being investigated for possible use in COVID-19 patients. SNG001 has been administered to hospitalised patients on top of standard of care which changed substantially between the Phase 2 and Phase 3 trials.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 21, 2022
Details:
SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries evaluating SNG001 for the treatment of hospitalised COVID-19 patients. Upon successful completion of the Phase III study, the company plans to file EUA with the USFDA.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SG018 Phase 3 trial is a randomised, double-blind, placebo-controlled study being conducted in 17 countries evaluating SNG001 for the treatment of hospitalised COVID-19 patients. Upon successful completion of the Phase III study, the company plans to fil...
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 11, 2021
Details:
In the Phase II portion of the study, SNG001 will be evaluated in up to 220 participants across multiple US sites, with a positive result leading into the Phase III portion of the study.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the Phase II portion of the study, SNG001 will be evaluated in up to 220 participants across multiple US sites, with a positive result leading into the Phase III portion of the study.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 15, 2021
Details:
Synairgen has completed the recruitment of 120 subjects in its Phase II trial of an inhaled formulation of interferon-beta-1a (SNG001) for treating ‘at risk’ Covid-19 patients in the home setting.
Lead Product(s): Interferon Beta-1A
Therapeutic Area: Infections and Infectious Diseases Brand Name: SNG001
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Synairgen has completed the recruitment of 120 subjects in its Phase II trial of an inhaled formulation of interferon-beta-1a (SNG001) for treating ‘at risk’ Covid-19 patients in the home setting.
Brand Name : SNG001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 20, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?